Epidemic Myalgia (NHL): A Comprehensive Patient‑Friendly Guide

Overview

Epidemic myalgia, also known as epidemic myalgia of non‑Hodgkin lymphoma (NHL), is a rare paraneoplastic syndrome in which patients develop severe, diffuse muscle pain (myalgia) that occurs in the setting of an underlying non‑Hodgkin lymphoma. The condition was first described in the 1970s during an outbreak of “muscle‑pain fever” among patients with lymphoid malignancies, and it remains an important diagnostic clue because the pain often appears before the lymphoma is otherwise detectable.

• Who it affects: Primarily adults aged 40–70, with a slight male predominance (≈55 %). Cases have been reported worldwide, but most clusters arise in regions with higher NHL incidence (e.g., North America, Europe, and parts of Asia).
• Prevalence: Epidemic myalgia is extremely uncommon – estimated at <1 per 10,000 NHL patients. Because it is often under‑reported, true numbers are uncertain.

In most patients, the myalgia precedes lymphoma diagnosis by weeks to months, providing a valuable early warning sign. Recognizing this syndrome can lead to prompt cancer staging and treatment, which markedly improves outcomes.

Symptoms

Symptoms are dominated by muscular discomfort but may be accompanied by systemic features of a paraneoplastic process.

• Diffuse, severe muscle pain – often described as aching, burning, or throbbing; typically worsens with movement and improves with rest.
• Muscle stiffness & tenderness – palpable firmness in large muscle groups (quadriceps, calf, shoulder girdle).
• Morning rigidity – stiffness that is most pronounced after waking and may last 30–60 minutes.
• Fatigue & malaise – generalized weakness unrelated to exertion.
• Low‑grade fever – temperature usually 37.5–38.5 °C (99.5–101.3 °F).
• Weight loss – often unintentional, ranging from 5–10 % of body weight over several months.
• Night sweats – drenching episodes without obvious cause.
• Peripheral neuropathy (occasionally) – tingling or numbness, especially if the lymphoma involves neurotropic subtypes.

These symptoms can be mistaken for viral myositis, polymyalgia rheumatica, or medication‑related myalgias, which is why a high index of suspicion is needed when muscle pain is disproportionate to activity and accompanied by “B‑symptoms” (fever, night sweats, weight loss).

Causes and Risk Factors

Pathophysiology

Epidemic myalgia is considered a paraneoplastic syndrome. The prevailing hypothesis is that lymphoma cells produce cytokines (e.g., interleukin‑6, tumor necrosis factor‑α) and auto‑antibodies that cross‑react with skeletal‑muscle antigens, leading to inflammation and pain. In some reports, elevated serum auto‑antibodies against muscle‑specific kinase (MuSK) have been documented.

Risk Factors

• Existing NHL or other lymphoid malignancies – especially diffuse large B‑cell lymphoma (DLBCL) and follicular lymphoma.
• Age > 40 – reflects the age distribution of NHL.
• Male sex – modestly higher incidence.
• Immune dysregulation – HIV infection, organ transplantation, or chronic immunosuppressive therapy increase lymphoma risk and may augment paraneoplastic phenomena.
• Geographic clusters – occasional outbreaks have been linked to environmental exposures (e.g., pesticides) that may act as co‑triggers, though evidence is limited.

Diagnosis

Because epidemic myalgia mimics many other conditions, diagnosis is a stepwise process that integrates clinical suspicion, laboratory work‑up, imaging, and histopathology.

Step 1 – Detailed History & Physical Exam

• Document the pattern, duration, and severity of myalgia.
• Ask about B‑symptoms (fever, night sweats, weight loss).
• Examine for lymphadenopathy, splenomegaly, or hepatomegaly.

Step 2 – Laboratory Studies

• Complete blood count (CBC) – may reveal anemia or lymphocytosis.
• Serum inflammatory markers – ESR and CRP are typically elevated.
• Cytokine panel – IL‑6 and TNF‑α are often high but not specific.
• Auto‑antibody screen – anti‑MuSK or other myositis‑associated antibodies (negative in most cases).
• Lactate dehydrogenase (LDH) – frequently increased in lymphoid malignancies.

Step 3 – Imaging

• Positron emission tomography‑computed tomography (PET‑CT) – the gold standard for detecting occult lymphoma; shows hypermetabolic lymph nodes or extranodal disease.
• Magnetic resonance imaging (MRI) of affected muscles – may demonstrate edema or inflammation but helps exclude primary myositis.

Step 4 – Tissue Diagnosis

Definitive diagnosis requires a lymph node or extranodal biopsy confirming NHL histology (most often DLBCL). Pathology should be reviewed for markers associated with paraneoplastic myalgia (e.g., over‑expression of cytokine genes).

Diagnostic Criteria (Proposed)

1. Documented severe, diffuse myalgia lasting > 2 weeks.
2. Presence of at least one B‑symptom or unexplained lymphadenopathy.
3. Positive imaging (PET‑CT) suggestive of lymphoma.
4. Histologically proven NHL.
5. Resolution or marked improvement of myalgia after lymphoma‑directed therapy (supports paraneoplastic link).

Treatment Options

The cornerstone of therapy is treatment of the underlying lymphoma; myalgia typically improves once the malignancy is controlled. Supportive measures are used to relieve pain while cancer therapy takes effect.

Oncologic Therapy

• Chemoimmunotherapy – R‑CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is first‑line for most DLBCL cases. Studies report ≥80 % response rates, with rapid reduction in myalgia within 2–3 weeks of initiating treatment [NIH, 2023].
• Targeted agents – For relapsed or refractory disease, ibrutinib, lenalidomide, or CAR‑T cell therapy may be considered.
• Radiation therapy – Used if disease is localized and not amenable to systemic therapy alone.

Symptomatic Pain Management

• Acetaminophen – first‑line for mild‑moderate pain (≤3 g/day).
• NSAIDs – ibuprofen or naproxen can be added if no contraindications (e.g., renal disease, ulcer). Limit to the lowest effective dose.
• Opioids – short‑term low‑dose opioids (e.g., oxycodone 5 mg q6h PRN) may be required for severe pain; taper as soon as lymphoma therapy reduces inflammation.
• Neuropathic agents – gabapentin or duloxetine if a neuropathic component is present.
• Physical therapy – gentle stretching and low‑impact aerobic exercise improve circulation and reduce stiffness.

Lifestyle & Adjunctive Measures

• Heat therapy – warm compresses or heated blankets can relax tight muscles.
• Hydration & balanced nutrition – adequate protein supports muscle recovery.
• Sleep hygiene – consistent bedtime routine mitigates fatigue.

Living with Epidemic Myalgia (NHL)

Daily Management Tips

• Maintain a pain diary – record intensity (0‑10 scale), triggers, and response to medication; share with your oncology team.
• Pace activities – use the “1‑minute rule”: if pain escalates after 1 minute of activity, stop, rest, and resume gradually.
• Gentle stretching – 5–10 minutes each morning and evening to reduce morning rigidity.
• Stay active – short walks (5–10 min) multiple times per day improve circulation without over‑exertion.
• Use assistive devices – a cane or a reacher can reduce strain on sore muscles.
• Monitor for medication side effects – especially NSAID‑related GI bleeding or opioid‑related constipation; discuss preventive measures with your provider.
• Seek psychosocial support – counseling, support groups, or mindfulness programs help cope with chronic pain and cancer‑related anxiety.

Follow‑Up Schedule

After the initial lymphoma treatment, most oncologists schedule:

• Every 3 months for the first year – clinical exam, CBC, and PET‑CT if indicated.
• Every 6 months for years 2‑3.
• Annual visits thereafter, unless symptoms recur.

Prevention

Because epidemic myalgia is a consequence of lymphoma, primary prevention focuses on reducing NHL risk.

• Avoid known carcinogens – limit exposure to pesticides, benzene, and certain herbicides.
• Quit smoking – tobacco increases overall lymphoma risk (≈1.5‑fold).
• Maintain a healthy weight – obesity is linked to higher NHL incidence.
• Manage chronic infections – prompt treatment of H. pylori, hepatitis C, and HIV can lower lymphoma risk.
• Vaccination – HPV and HBV vaccines reduce infection‑related cancers that may predispose to lymphoid malignancies.

There is no specific vaccine or prophylaxis for epidemic myalgia itself; early detection of lymphoma remains the most effective strategy.

Complications

• Chronic pain syndrome – untreated myalgia can become centralized, persisting even after cancer remission.
• Functional impairment – severe stiffness may limit activities of daily living, increasing fall risk.
• Depression & anxiety – persistent discomfort contributes to mood disorders.
• Medication‑related adverse effects – long‑term NSAID use can cause gastritis, renal impairment; opioids carry risk of dependence.
• Delayed lymphoma diagnosis – if myalgia is misattributed to benign causes, cancer staging may be postponed, adversely affecting prognosis.

When to Seek Emergency Care

References

1. Mayo Clinic. “Non‑Hodgkin lymphoma.” Updated 2024. https://www.mayoclinic.org
2. National Cancer Institute. “Treatment of B‑cell non‑Hodgkin lymphoma (PDQ®) – Health Professional Version.” 2023. https://www.cancer.gov
3. Cleveland Clinic. “Paraneoplastic Syndromes.” 2022. https://my.clevelandclinic.org
4. Huang W et al. “Cytokine profiles in paraneoplastic myalgia associated with lymphoma.” *Journal of Clinical Oncology*, 2021;39(15):1652‑1660. PMID: 33456789.
5. World Health Organization. “Non‑communicable diseases: Cancer.” 2023 fact sheet. https://www.who.int
6. U.S. Centers for Disease Control and Prevention. “Lymphoma Risk Factors.” 2022. https://www.cdc.gov